1. Home
  2. GNS vs RNTX Comparison

GNS vs RNTX Comparison

Compare GNS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genius Group Limited

GNS

Genius Group Limited

HOLD

Current Price

$0.45

Market Cap

48.0M

Sector

Real Estate

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

N/A

Current Price

$1.60

Market Cap

42.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GNS
RNTX
Founded
2002
2001
Country
Singapore
United States
Employees
N/A
10
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
48.0M
42.9M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
GNS
RNTX
Price
$0.45
$1.60
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
917.9K
118.2K
Earning Date
03-09-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$156.26
N/A
Revenue Next Year
$35.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.24
$1.02
52 Week High
$1.92
$2.22

Technical Indicators

Market Signals
Indicator
GNS
RNTX
Relative Strength Index (RSI) 60.10 68.31
Support Level $0.36 $1.08
Resistance Level $0.48 $2.18
Average True Range (ATR) 0.04 0.18
MACD 0.01 0.03
Stochastic Oscillator 88.53 89.83

Price Performance

Historical Comparison
GNS
RNTX

About GNS Genius Group Limited

Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. Its revenue is derived from five reportable segments: Central, Academy, School, Resorts, and Discontinued operations. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: